Table 1. Baseline characteristics.
| Characteristic | Number (%) |
|---|---|
| Age, yrs. | |
| Median | 50.9 |
| Range | 26–87 |
| T stage | |
| T1 | 163 (51.1) |
| T2 | 148 (46.4) |
| T3 | 5 (1.6) |
| T4 | 3 (0.9) |
| N stage | |
| N0 | 183 (57.4) |
| N1 | 91 (28.5) |
| N2 | 24 (7.5) |
| N3 | 21 (6.6) |
| Histologic subtype | |
| No special type | 288 (90.3) |
| Lobular | 6 (1.9) |
| Micropapillary | 5 (1.6) |
| Metaplastic | 9 (2.8) |
| Mucinous | 7 (2.2) |
| Others | 4 (1.3) |
| Histologic grade | |
| I | 45 (14.1) |
| II | 94 (29.5) |
| III | 180 (56.4) |
| LVI | |
| Absent | 173 (54.2) |
| Present | 146 (45.8) |
| P53 overexpression | |
| Negative | 221 (69.3) |
| Positive | 98 (30.7) |
| Ki-67 | |
| < 20% | 166 (52.0) |
| ≥ 20% | 153 (48.0) |
| ER | |
| Negative | 98 (30.7) |
| Positive | 221 (69.3) |
| PR | |
| Negative | 145 (45.5) |
| Positive | 174 (54.5) |
| HER2 | |
| Negative | 238 (74.6) |
| Positive | 81 (25.4) |
| Subtype | |
| Luminal A | 119 (37.3) |
| Luminal B | 104 (32.6) |
| HER2+ | 40 (12.5) |
| Triple-negative | 56 (17.6) |
| Adjuvant chemotherapy | |
| Not received | 48 (15.0) |
| Received | 265 (83.1) |
| Unknown | 6 (1.9) |
| Adjuvant radiotherapy | |
| Not received | 137 (42.9) |
| Received | 176 (55.2) |
| Unknown | 6 (1.9) |
| Adjuvant hormone therapy | |
| Not received | 106 (33.2) |
| Received | 207 (64.9) |
| Unknown | 6 (1.9) |
LVI, lymphovascular invasion; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2